This drug should not be co-administered with dofetilide or rifampin. Dofetilide when taken with<unk>  can cause an increase in dofetilide plasma concentrations, which can lead to death. Rifampin and<unk>  when taken together can decrease<unk>  plasma concentrations and cause resistance to<unk> . Other HIV-1 antiretroviral drugs should not be taken with this therapy. If kidney disease or development of renal impairment is seen, the drug should be discontinued. Discontinuation of<unk>  in patients with hepatitis B and HIV-1 has been shown to increase the prevalence of hepatitis B, causing liver decompensation and liver failure Adverse drug reactions include, but are not limited to, diarrhea, nausea, and headache.
Bictegravir/emtricitabine/tenofovir alafenamide
Doravirine/lamivudine/tenofovir
Dolutegravir/lamivudine/tenofovir
Lamivudine/tenofovir
Atazanavir/ritonavir
Abacavir/lamivudine/zidovudine
Emtricitabine/rilpivirine/tenofovir
Abacavir/lamivudine